Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
2019: PT-141 received FDA approval (as bremelanotide) for hypoactive sexual desire disorder (HSDD) in premenopausal women, following successful RECONNECT Phase III trials (Kingsberg et al., 2019)
N.BondyS
As weight decreases, there is often less fat around the neck and airway
Limited peptide manufacturing capacity is likely to keep supply tight until new facilities reach full output in 2027
Rates of treatment discontinuation varied across dosing regimens from 0 to 17% (vs
US$ 29.86
US$ 27.84
US$ 27.53
US$ 24.93
US$ 21.77
